$SRNG .01 Shelron Group Subsidiary Signs Agreement to

New Post Public Reply Private Reply Replies (0) Message Board
jstops

[b]$SRNG[/b] .01 Shelron Group Subsidiary Signs Agreement to Acquire Gold Exploration Licenses in Chile

Estimated Resources of 740,000 oz of Gold Valued in Excess of $1 Billion

NEW YORK, [b][color=blue]Oct 5, 2012[/color][/b] (GlobeNewswire via COMTEX) -- Shelron Group , Inc. (OTC:SRNG) or the "Company", is pleased to announce that on August 9, 2012, the Company's Serena Gold subsidiary executed a binding agreement to acquire gold exploration licenses in Chile.

The prospect is 4,450 acres, and the Company has received an appraisal showing estimated resources of 740,000 oz of gold, having a current market value in excess of $1 Billion.

Pursuant to the Agreement of Unilateral Option for the Purchase of Mining Concessions, Serena acquired the right to explore certain specified gold mining properties in the country of Chile.

In the past years, several sections of the deposit's ore bodies with high gold and copper content had been exploited by miner teams using bore pits and associated drifts, as well as fissure-type open-cast mines and galleries with a length of up to 100 meters.

The licensed area deposit is limited to an extended ore belt, characterized with a wide development of copper-gold, copper, and especially gold deposits. The deposit is located in the block of an Upper Cretaceous granitoid massif, bursting through a layer of volcano sedimentary Lower Cretaceous formations. The massif is broken up with a series of extended north-east and north-west fissures, confined to which are both acidic-composition and main-composition dykes, as well as quartz veins. The latter are younger in relation to the dykes.

Over 30 quartz veins have been detected within the ore field, most of these containing gold and copper-gold mineralization. About 20 of these are developed within the borders of the concessions. The vein bodies are connected to fissures with a prevailing north-west direction, with a steep (70-90 degree) decline to the west. The average width of the veins is 0.4-05 meters, with a variation from 0.1 to 2 meters with the tendency for width increase with depth. Their length is between 100 and 3,000 meters. As a rule, the veins are separated from each other to a distance of several dozen to several hundred meters. The veins possess off-shoots with a length of 10-20 meters or more.

In the years 1996-1998 exploratory and evaluation surveys had been carried out on this territory by AIGM-Chile, which had carried out a schematic geological and geomorphologic mapping of the ore field, testing of the vein bodies in existing ore developments, as well as geochemical sampling of the central area of the ore field. Based on these results, predicted geological resources of gold in the territory of the ore field have been estimated at 53.7 tons, while the resources of the three most explored veins in the mining properties of AIGM-Chile have been evaluated at the sum of categories P1-C2 to be at 11.2 tons.

In 1999 the aforementioned veins have been tested by workers of INPPA S.A Ltda. The data received was a broad confirmation of the AIGM-Chile conclusions.

This is a great opportunity for Serena Gold LLC as for Shelron Group to develop its portfolio in South America.

The purchase agreement is subject to a payment of $500,000 in 24 months and a completion of geological surveys .

About Shelron Group

Shelron Group, Inc. (OTC:SRNG) is a New York based mineral exploration and development company focused on acquisition, exploration, evaluation, and development of mineral resource properties in Africa and South America. The Company incorporated in Delaware and is headquartered in New York.

Additional information is available at http://www.Shelron-Group.com.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 188

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
PASCAL's Holiday Gift Edit: Timeless Watches Shine

Updated Category News Views 384

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 260

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
Webull Faces Class Action: Key Details for Investors

Updated Category News Views 267

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 392

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Retirement Dreams Dashed: 61% Withdraw Early

Updated Category News Views 382

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

Continue Reading
Luvme Hair Offers Wig Variety for Winter Fashion

Updated Category News Views 371

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

Continue Reading
El Pollo Loco Faces Class Action Over Wage Practices

Updated Category News Views 472

Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 344

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 433

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
/news?page=2">More News Articles